|
 Insulin aspart, with the global trade name NovoRapid, has been on the market worldwide for more than a decade for the treatment of diabetes mellitus.Fiasp is insulin aspart in a new formulation.Compared to NovoRapid, Fiasp contains two additional excipients: nicotinamide (also known as niacinamide or vitamin B3) and L-arginine hydrochloride (an amino acid). The addition of nicotinamide result in a faster initial absorption of insulin aspart following subcutaneous injection. The addition of L-arginine hydrochloride support stabilisation of the Fiasp formulation.
Fiasp is the world’s first ultra-fast acting insulin with twice as fast onset of appearance and two-fold greater early insulin exposure compared to insulin aspart. It has 74% greater insulin action within first 30 mins. US FDA approved fast-acting insulin aspart for the treatment of adults with diabetes in September 2017 and the formulation is available in India since March 2019. |
